Cargando…
Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784849/ https://www.ncbi.nlm.nih.gov/pubmed/35083213 http://dx.doi.org/10.3389/fcell.2021.755135 |
_version_ | 1784638830528167936 |
---|---|
author | Zhu, Lingling Liu, Yanyang Gao, Honglin Liu, Jiewei Zhou, Qinghua Luo, Feng |
author_facet | Zhu, Lingling Liu, Yanyang Gao, Honglin Liu, Jiewei Zhou, Qinghua Luo, Feng |
author_sort | Zhu, Lingling |
collection | PubMed |
description | The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC. Here, we present a 76-year-old male smoker harboring LUAD with a novel p. N771delinsGF deletion/insertion mutation in EGFR ex20 transdifferentiating from advanced LUSC after chemoradiotherapy. The patient presented reduced hydrothorax and relieved tightness with the treatment of nivolumab plus docetaxel and carboplatin after the failure of second-line chemotherapy. The case highlights the importance of rebiopsy and molecular retesting after the progression of lung cancer and supports the idea that the combination of immune checkpoint blockade and chemotherapy may be an attractive option for patients with EGFR ex20 mutations associated with LUSC–LUAD transformation. |
format | Online Article Text |
id | pubmed-8784849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87848492022-01-25 Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma Zhu, Lingling Liu, Yanyang Gao, Honglin Liu, Jiewei Zhou, Qinghua Luo, Feng Front Cell Dev Biol Cell and Developmental Biology The histological transformation from lung squamous cell carcinoma (LUSC) to lung adenocarcinoma (LUAD) and p. N771delinsGF mutations in EGFR exon 20 (ex20) are exceedingly rare in non–small cell lung carcinoma (NSCLC). EGFR ex20 mutations are insensitive to EGFR tyrosine kinase inhibitors in NSCLC. Here, we present a 76-year-old male smoker harboring LUAD with a novel p. N771delinsGF deletion/insertion mutation in EGFR ex20 transdifferentiating from advanced LUSC after chemoradiotherapy. The patient presented reduced hydrothorax and relieved tightness with the treatment of nivolumab plus docetaxel and carboplatin after the failure of second-line chemotherapy. The case highlights the importance of rebiopsy and molecular retesting after the progression of lung cancer and supports the idea that the combination of immune checkpoint blockade and chemotherapy may be an attractive option for patients with EGFR ex20 mutations associated with LUSC–LUAD transformation. Frontiers Media S.A. 2022-01-10 /pmc/articles/PMC8784849/ /pubmed/35083213 http://dx.doi.org/10.3389/fcell.2021.755135 Text en Copyright © 2022 Zhu, Liu, Gao, Liu, Zhou and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Zhu, Lingling Liu, Yanyang Gao, Honglin Liu, Jiewei Zhou, Qinghua Luo, Feng Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma |
title | Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma |
title_full | Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma |
title_fullStr | Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma |
title_full_unstemmed | Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma |
title_short | Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma |
title_sort | case report: partial response following nivolumab plus docetaxel in a patient with egfr exon 20 deletion/insertion (p.n771delinsgf) mutant lung adenocarcinoma transdifferentiated from squamous cell carcinoma |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784849/ https://www.ncbi.nlm.nih.gov/pubmed/35083213 http://dx.doi.org/10.3389/fcell.2021.755135 |
work_keys_str_mv | AT zhulingling casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma AT liuyanyang casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma AT gaohonglin casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma AT liujiewei casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma AT zhouqinghua casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma AT luofeng casereportpartialresponsefollowingnivolumabplusdocetaxelinapatientwithegfrexon20deletioninsertionpn771delinsgfmutantlungadenocarcinomatransdifferentiatedfromsquamouscellcarcinoma |